Henry Ford Health

Henry Ford Health Scholarly Commons
Nephrology Articles

Nephrology

1-1-2019

Clostridioides difficile Infection in Chronic Kidney Disease/EndStage Renal Disease
Mayur Ramesh
Henry Ford Health, MRAMESH1@hfhs.org

Jerry Yee
Henry Ford Health, JYEE1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/nephrology_articles

Recommended Citation
Ramesh M, Yee J. Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease.
Advances in chronic kidney disease 2019; 26(1):30-34.

This Article is brought to you for free and open access by the Nephrology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Nephrology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

ACKD

Clostridioides difficile Infection in Chronic
Kidney Disease/End-Stage Renal Disease
Mayur S. Ramesh and Jerry Yee
Clostridioides difficile infection (CDI) is a major health-care burden and increasingly seen in patients with chronic kidney disease
(CKD) and end-stage renal disease (ESRD). Increased antibiotic use, alteration in host defenses, and gastric acid suppression are
some of the etiologies for increased risk of CDI in these populations. Patients with CKD/ESRD have a higher risk of initial
episode, recurrence, and development of severe CDI than those without CKD or ESRD. Diagnosis and management of CDI in
patients with CKD/ESRD are similar to that in the general population. The mortality, length of stay, and health-care costs are
higher in patients with CDI and CKD/ESRD. Antimicrobial stewardship with reduction in antibiotic use along with infectioncontrol measures such as contact isolation and hand hygiene with soap and water is essential in the control and prevention
of CDI in patients with CKD/ESRD.
Q 2019 by the National Kidney Foundation, Inc. All rights reserved.
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C

hronic kidney disease (CKD) and end-stage renal disease (ESRD) represent major health-care problems
with signiﬁcant morbidity and cost. In patients with
CKD/ESRD, infections are common, and consequently
antibiotic exposure is increased.1,2 Clostridioides difﬁcile
(previously Clostridium difﬁcile) infection (CDI) is the
most common cause of heath-care–associated diarrhea.
CKD and ESRD are now recognized as risk factors for
CDI.3 CKD/ESRD also increases the risk for recurrent
CDI and is associated with higher mortality.4 CDI in patients with CKD/ESRD also adds to the duration of hospitalization and cost.5 Reducing antibiotic use and enforcing
stricter infection-control policies are essential to prevent
CDI in this population.6

leukocytosis. The diagnosis of CDI is ideally established
by a stepwise algorithm of initial, positive stool testing
for glutamate dehydrogenase and C. difﬁcile toxins A and
B by enzyme immunoassay (EIA) and reﬂexed to nucleic
acid ampliﬁcation (NAAT) testing for the toxin B gene in
case of indeterminate EIA results.6 Ordering and interpretation of stool testing for CDI should be based on pretest
probability, which involves the presence of diarrhea and
a change in characteristic of the stools from baseline.
Management strategies include discontinuation of the
inciting antibiotic followed by the administration of oral
vancomycin or ﬁdaxomicin.6 Adherence to strict
infection-control policies such as contact precautions and
hand hygiene with soap and water is critical for prevention
of nosocomial transmission.6

OVERVIEW OF CDI
Clostridioides difﬁcile is a gram-positive, anaerobic, sporeforming, toxin-producing bacterium and causes
antibiotic-associated diarrhea and colitis. Typically, colonization of the intestine occurs via the fecal-oral route.
Disruption of normal intestinal microbiota (dysbiosis),
usually by antibiotics, can result in CDI.7 Colonization of
C. difﬁcile is facilitated in patients with intestinal dysbiosis
by pathogenic toxin production and altered host immune
responses.7 Well-established risk factors for CDI include
advanced age (.65 years), health-care exposure, hospitalization, and antibiotic use6 (Table 1). CDI can manifest as a
spectrum of clinical manifestations from asymptomatic
carriage to fulminant colitis.6 Typically, it results in watery
diarrhea ($3 episodes of loose stools in 24 hours) with
associated low-grade fever, lower abdominal pain, and

RISK OF INFECTIONS IN CKD/ESRD
The appearance of immune dysfunction is common in
advanced CKD and particularly during ESRD. Alterations
in both the innate and adaptive immune systems occur in
CKD/ESRD cases, with consequent increased risk of bacterial infections.8
Infections are common in patients with ESRD at a rate of
5.7 events per 1000 dialysis-days.2 Urinary tract infections,
pneumonia, and sepsis from central venous catheters are
the most common infections in patients with ESRD.1 Patients with ESRD are often hospitalized at least twice a
year, with a 30-day readmission rate of 35%, an increased
length of stay, and 2%-5% risk of nosocomial infections.2,9
These factors result in excessive antibiotic use and
consequently an increased risk of CDI. Patients with
ESRD are also at risk of infection due to multidrugresistant organisms, and antibiotic stewardship practices
are required to curtail the overuse of broad-spectrum antibacterial agents.10 The most likely risk factors for CDI in
patients with CKD/ESRD include impaired immune function, increased antibiotic exposure, and gastric acid suppression.
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EPIDEMIOLOGY OF CDI IN CKD/ESRD
A 14% prevalence of CKD in the United States has been reported over the past decade, with increasing diagnosis of
ESRD.9,11 Patients with CKD/ESRD are especially
vulnerable to the development of CDI, attributable to
Adv Chronic Kidney Dis. 2019;26(1):30-34
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frequent antibiotic exposure and other associated risk
was illustrated in uremic patients who developed severe
factors. CDI and recurrent CDI have long been reported
CDI with systemic toxicity.18 The various clinical manifestations of CDI are detailed in Table 2.
in patients with CKD and ESRD. In a hospital
Asymptomatic carriage is more common in patients with
environment, the incidence of CDI was higher in the
CKD. Patients without diarrhea admitted to 2 tertiary care
nephrology department than in other departments as
hospitals in Australia had higher risk of colonization with
documented in an older, retrospective study.12
Based on the US National Hospital Discharge Survey
toxigenic and nontoxigenic C. difﬁcile when CKD was one
(NHDS), 5% of 162 million patients discharged from
of the clinical diagnoses.19 Most patients with CKD or
ESRD present with multiple episodes of watery diarrhea
2005 to 2009 had CKD. CDI occurred at a rate of 1.49%
with mucus and/or foul odor. Associated clinical manifescompared with 0.70% in patients with and without CKD,
tations include lower abdominal pain/cramps, low-grade
respectively.4 Patients with ESRD were twice as likely to
develop CDI compared with non-CKD patients in this
fever, volume depletion, electrolyte imbalance, and leukostudy (P , 0.001). In a study of all adult patients with a
cytosis. Most individuals have an indolent course,
discharge diagnosis of ESRD or CDI from the US Nationwhereas others may develop a severe disease that can
wide Inpatient Sample 2009 database, CDI appeared in
progress to toxic megacolon and/or intestinal perforation
2.8% of individuals with ESRD.13 A meta-analysis of 20
and death.
case-control, cohort, and cross-sectional studies revealed
The diagnosis of CDI should be suspected in patients
pooled relative risks (RRs) of primary CDI of 1.95 (95%
with $3 episodes of loose stools in a 24-h period, with a
conﬁdence interval [CI], 1.81 to 2.10) and 2.63 (95% CI,
change in the character of stool from baseline (usually
2.04 to 3.38) in patients with CKD and ESRD, respecloose stools with mucus and foul odor). Although stool
tively.14
testing for C. difﬁcile toxin B gene by NAAT is highly senIn a case-control study of 188 patients with CDI
sitive, it is unable to differentiate between asymptomatic
compared with age- and sex-matched controls without
colonization and active infection. An ideal approach to
CDI, no signiﬁcant difference
stool testing for CDI (in paoccurred in prevalence of
tients experiencing diarCLINICAL SUMMARY
advanced CKD (odds ratio
rhea) may be a stepwise
[OR], 1.38; 95% CI, 0.90 to
algorithm involving a com The epidemiology of Clostridioides difficile infection (CDI)
2.12; P ¼ 0.137).15 However,
bination of EIA for glutaidentifies the greater disease burden in chronic kidney
disease (CKD)/end-stage renal disease (ESRD).
patients with ESRD undergomate dehydrogenase/toxin
ing dialysis had a signiﬁcant
testing with reﬂex NAAT
 Diagnosis and management of CDI in patients with CKD/
association (OR, 2.60; 95%
testing in case of indetermiESRD are similar to that in the general population.
CI, 1.25 to 5.41; P ¼ 0.017).
nate EIA results.6 The char Patients with CKD/ESRD have greater risks of recurrent and
acteristics of general tests
Advanced CKD increased
severe CDI, and both are associated with greater mortality,
used for diagnosing CDI
CDI risk was recorded in a
length of hospitalization, and health-care costs.
are displayed in Table 3.
South Korean study of CDICurrently, repeat stool
positive patients (n ¼ 171)
 Infection-control and antimicrobial stewardship measures
are essential for control of CDI in the CKD/ESRD population.
testing for CDI is not recomand CDI-negative age- and
mended within 7 days of the
sex-matched
controls
same diarrheal episode.6
(n ¼ 342). Patients with stages
Clinical cure is achieved with resolution of diarrhea.
4/5 CKD who were not undergoing renal replacement
Stool-testing modalities should be avoided as demonstratherapy by dialysis and patients with ESRD who were
tive of “cure” because of high false-positive rates after an
on dialysis had respective ORs of 2.9 and 4.9 for the risk
initial episode of CDI. Imaging modalities including
of CDI.16 This differential rate of CDI was also detected
in another recent, retrospective analysis from Poland in
computed tomography of the abdomen/pelvis and lower
which 67% of patients who tested positive for CDI had
gastrointestinal endoscopy for recognition of mucosal
CKD stage 5 compared with 5.7% who had CKD stage
pseudomembranes can be used in selected patients.
1.17 The NHDS database revealed that CDI rates were
The primary management of CDI should include discongreater with advancing CKD: 43.5% in CKD stage 5 on
tinuation of the inciting antibiotic where applicable. For an
renal replacement therapy; 21.2% in CKD stages 3, 4, and
initial episode of CDI, oral vancomycin (125 mg every
5; and only 2.46% in CKD stages 1 and 2.4
6 hours) or ﬁdaxomicin (200 mg every 12 hours) is
preferred over oral metronidazole (500 mg every 8 hours).6
CLINICAL MANIFESTATIONS, DIAGNOSIS, AND
The treatment duration for most patients with CDI is
10 days. For fulminant CDI, a high dose of oral vancomyMANAGEMENT OF CDI IN CKD/ESRD
cin (500 mg every 6 hours) with intravenous metronidaCDI may unfold a spectrum of clinical manifestations from
asymptomatic carriage to mild diarrhea, severe disease
zole is recommended, although supporting data are
limited.6 In a post hoc analysis of 2 randomized, controlled
with pseudomembranous colitis, or even fulminant colitis
phase 3 clinical trials of vancomycin vs ﬁdaxomicin therwith death. The clinical manifestations of CDI in patients
apy as a treatment of CDI, the time to resolution of diarwith CKD are similar to those experienced by the general
rhea was greater for CKD stages 3 or 4 than that for
population. However, patients with advanced CKD and
stage 2.20 Also, patients with CKD stage 3 or higher with
ESRD are more likely to develop severe CDI. This concept
Adv Chronic Kidney Dis. 2019;26(1):30-34
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Table 1. Risk Factors for Clostridioides difficile Infection
Traditional

Additional

Age . 65 years
Recent hospitalization
Increased hospital length
of stay
Long-term health-care
facility residence
Antibiotic exposure
Comorbidities such as
malignancy, CKD/ESRD,
inflammatory bowel
disease,
immunosuppression

Contact with active carriers
Consumption of contaminated
food products such as processed
meats
Hypoalbuminemia
Use of proton-pump inhibitors
Gastrointestinal endoscopic
procedures
Enteral tube feeding

Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal
disease.
Data from McDonald et al.6

CDI had lower odds of cure and greater probability of
recurrence. Cure rates were similar in both vancomycin
and ﬁdaxomicin groups. Notably, the vancomycin group
had higher recurrence rates, independent of renal function.
No dose adjustment is needed for oral vancomycin or ﬁdaxomicin in patients with CKD/ESRD due to lack of absorption from gut lumen. Intravenous vancomycin has
no role in the management of CDI.
Surgical management in the form of subtotal colectomy
with preservation of the rectum is generally reserved for
cases with fulminant CDI with acute abdomen, megacolon, perforation, or septic shock with organ dysfunction.6
An alternative procedure of loop ileostomy with antegrade vancomycin lavage is a less morbid and colonpreserving procedure.21 Probiotics have been helpful in
prevention of antibiotic-associated diarrhea but are of
minimal beneﬁt in prevention of CDI.6 Anion-binding
resins are not recommended in the acute management of
CDI.6
RECURRENT CDI IN PATIENTS WITH CKD/ESRD
CDI is considered as recurrent when the infection occurs
within 8 weeks of onset of the index infection.6 Severe
and recurrent CDIs have been reported in patients with
CKD. After treatment of CDI, the risk of recurrence is at
least 20%, with a possibly greater risk in patients with
CKD/ESRD. In a meta-analysis of 20 case-control, cohort,
Table 2. Clinical Manifestations of Clostridioides difficile Infection
(CDI)
Asymptomatic Carriage
Mild to moderate

Severe

Fulminant
Data from McDonald et al.6

No Clinical Symptoms With
Positive Stool Testing for CDI
Peripheral blood white blood
cell count , 15 3 109/L, serum
creatinine level , 1.5 mg/dL
Peripheral blood white blood
cell count $ 15 3 109/L, serum
creatinine level . 1.5 mg/dL
Severe hypotension, shock,
ileus, or megacolon

and cross-sectional studies, the pooled RR of recurrent
CDI in patients with CKD was 2.61 (95% CI, 1.53 to
4.44).14 The risk of recurrence increases as episodes of
CDI increase. The risk factors for recurrent CDI in patients
with CKD/ESRD includes age over 65 years, repeat antibiotic exposure, and severe primary CDI (similar to patients without CKD/ESRD).
Treatment of the initial episode of recurrent CDI repeats
the standard course of oral vancomycin or ﬁdaxomicin.6
Additional recurrences are generally treated with a
tapered and pulsed course of oral vancomycin.6 Oral vancomycin followed by a rifaximin “chaser” is an alternative
strategy.6 Fecal microbiota transplantation (FMT) is
increasingly used as treatment for recurrent CDI for the
prevention of recurrences in persons who have failed multiple courses of antibiotics.6
NOVEL THERAPIES FOR CDI IN PATIENTS WITH CKD/
ESRD
Bezlotoxumab (Merck and Co.) is a monoclonal antibody
directed against toxin B of C. difﬁcile. This antibody was
recently approved by the Food and Drug Administration
for prevention of relapsing CDI.22 Bezlotoxumab is administered as a single, intravenous dose (10 mg/kg) to provide
passive immunity for at least 3 months’ duration in patients with a history of CDI. It reduces the risk of an initial
posttreatment CDI relapse by 40% compared with standard antibiotic treatment.22 The global phase 3 clinical trials, MODIFY I and MODIFY II, determined the safety and
efﬁcacy of bezlotoxumab and included patients with CKD.
However, the trials were not speciﬁcally designed to determine beneﬁts in patients with CKD.23 Bezlotoxumab is
beneﬁcial when given during the standard treatment of
CDI and reduces the risk of recurrence in 1 of 6-10 patients
compared with standard antibiotic therapy. The cost of this
agent must be weighed against the expense for other C.
difﬁcile treatment modalities such as FMT.
FMT is currently recommended to prevent further
relapse in patients with more than 2 episodes of CDI.
FMT is considered safe, effective, and durable.6 FMT repairs the intestinal dysbiosis of CDI via administration of
microbiota from a healthy prescreened donor. Clinical trials reported a success rate of FMT ranging from 44% to
96% for the prevention of recurrent CDI, applying various
formulations of FMT including fresh, frozen, and encapsulated organisms via inoculation by several delivery routes
(oral, nasogastric/duodenal, enema, or colonoscopy).24,25
Patients with CKD and ESRD have been included in
multiple clinical trials and anecdotal case series of FMT
for the management of CDI. The role of FMT to treat
primary and refractory CDI or severe/complicated CDI
remains anecdotal at present. Commercial microbiota
products, including RBX2660 and SER 109/262, for the
treatment of recurrent CDI are in clinical trial stages.26,27
Several new drugs such as ridinilazole are undergoing
evaluation in clinical trials for treatment/prevention of
relapse in CDI.28 Vaccines containing formalininactivated toxins A and B and recombinant toxins against
CDI are also being investigated in clinical trials.29,30
Nontoxigenic C. difﬁcile strains such as Nontoxigenic C.
Adv Chronic Kidney Dis. 2019;26(1):30-34
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Table 3. Common Clinical Testing for Clostridioides difficile Infection
Test

Detected Substance

Sensitivity

Specificity

Toxin A and B enzyme immunoassays (EIAs)
Glutamate dehydrogenase (usually combined
with EIAs for toxins)
Nucleic acid amplification test

Free toxins
Clostridioides difficile common antigen

Low
High

Moderate
Low

Clostridioides difficile gene for toxin

High

Low

6

Modified and reprinted from McDonald et al.

difﬁcile–M3 spores have been successful in preventing
recurrent CDI in a phase 2 clinical trial.30
OUTCOMES AND COST OF CDI IN PATIENTS WITH
CKD/ESRD
CDI is associated with signiﬁcant morbidity/mortality, hospital length of stay, and health-care–related costs. An analysis of the US NHDS database disclosed that CKD patients
with CDI compared with uninfected CKD patients had
longer hospitalizations, higher colectomy rates (adjusted
OR [aOR], 2.30; 95% CI, 2.14 to 2.47), discharges to a
health-care facility (aOR, 2.22; 95% CI, 2.19 to 2.25), and
increased in-hospital mortality (aOR, 1.55; 95% CI, 1.52 to
1.59; all P , 0.001).4 In a meta-analysis of 4 cohort studies
with more than 8 million participants, the pooled RR of mortality attributed to CDI was 1.73 (95% CI, 1.39 to 2.15) in patients with CKD.31 In the same analysis, patients with ESRD
had a pooled RR of mortality of 2.15 (95% CI, 2.07 to 2.23). In
a retrospective, case-control study, patients with advanced
CKD (estimated glomerular ﬁltration rate , 30 mL/min
per 1.73 m2) experienced greater in-hospital mortality.16 In
the US Nationwide Inpatient Sample database, all-cause, unadjusted in-hospital mortality was signiﬁcantly greater for
CDI patients with ESRD than for those without CDI
(11.6% vs 7.7%; P , 0.001).13 ESRD patients with CDI had
longer hospitalization by 2 days and greater hospitalization
costs than the non-ESRD group ($35,588 USD vs $23,505
USD, indexed to the value of the 2013 dollar; P , 0.001).5
In an analysis of hospital episode data from 4 European
countries, patients with comorbidities including CKD,
chronic obstructive pulmonary disease, heart failure, and
diabetes had increased length of stay attributable to the diagnosis of CDI.32
INFECTION CONTROL MEASURES FOR CDI IN
PATIENTS WITH CKD/ESRD
Patients with suspected CDI should be immediately
placed in contact isolation requiring gloves/gowns, with
pending stool test results.6 Hand hygiene should be performed with soap and water during the care of patients
with CDI. Soap and water handwashing is more effective
in eliminating C. difﬁcile spores than alcohol-based hand
sanitizers.6 Contact isolation may be discontinued after
48 hours after the disappearance of diarrhea.6 CDI incidence rates decreased signiﬁcantly (by 33% to .90%) after
implementation of an antimicrobial stewardship program
involving the reduction of antibiotic use. This observation
was concluded from the results of 15 quasiexperimental

studies published between 1994 and 2013.6 Antimicrobial
stewardship that stringently minimizes high-risk
antibiotic use will facilitate the reduction of CDI in all patients, including those with CKD/ESRD.
CONCLUSION
CDI is more common in patients with CKD/ESRD and is
associated with more severe disease and increased mortality.
Length of hospitalization and health-care costs escalate after
the development of CDI in patients with CKD/ESRD. Management of CDI is similar in patients with or without CKD/
ESRD. Oral vancomycin or ﬁdaxomicin is favored over oral
metronidazole in the initial management as per the current
CDI guidelines.6 Stricter adherence to infection-control measures and antimicrobial stewardship practices will reduce
the burden of CDI in the CKD/ESRD population.
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